The Cuban Center for Genetic Engineering and Biotechnology (CIGB) has reported that clinical studies of the candidate nasal vaccine against COVID-19 baptized as Mambisa have yielded positive results, so it will be proposed as a booster dose.
"The results of the clinical studies with the nasal vaccine candidate anticovid19 Mambisa designed by the CIGB are already being processed (…). We can anticipate that they are positive and that they can justify an authorization to be used as a booster dose"the CIGB has published in a message on Twitter.
Mambisa is one of the eleven possible vaccines designed throughout the world for nasal application. Four of them are already in the clinical studies phase.
Unlike injectable vaccines, nasal vaccines stimulate local immunogenicity in the mucous membranes, the site of entry of the pathogen, which allows its early neutralization.
